List of Excipients in Branded Drug SEGLENTIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kowa Pharmaceuticals America Inc	SEGLENTIS	celecoxib and tramadol hydrochloride	66869-564	CELLULOSE, MICROCRYSTALLINE	2031-06-03
Kowa Pharmaceuticals America Inc	SEGLENTIS	celecoxib and tramadol hydrochloride	66869-564	COPOVIDONE K25-31	2031-06-03
Kowa Pharmaceuticals America Inc	SEGLENTIS	celecoxib and tramadol hydrochloride	66869-564	CROSPOVIDONE	2031-06-03
Kowa Pharmaceuticals America Inc	SEGLENTIS	celecoxib and tramadol hydrochloride	66869-564	MANNITOL	2031-06-03
Kowa Pharmaceuticals America Inc	SEGLENTIS	celecoxib and tramadol hydrochloride	66869-564	POLYETHYLENE GLYCOL	2031-06-03
Kowa Pharmaceuticals America Inc	SEGLENTIS	celecoxib and tramadol hydrochloride	66869-564	SODIUM LAURYL SULFATE	2031-06-03
Kowa Pharmaceuticals America Inc	SEGLENTIS	celecoxib and tramadol hydrochloride	66869-564	SODIUM STEARYL FUMARATE	2031-06-03

Seglentis Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Seglentis is an immediate-release oral co-crystal containing celecoxib and tramadol hydrochloride. Each tablet delivers 56 mg of celecoxib and 44 mg of tramadol hydrochloride, equivalent to 37.5 mg of tramadol. The product’s commercial opportunity is tied to its dual-mechanism pain profile, while its formulation opportunity is concentrated in excipient systems that preserve co-crystal integrity, support rapid dissolution, and control tablet robustness without increasing manufacturing complexity.

The main strategic constraint is that Seglentis is a drug-drug co-crystal, not a conventional fixed-dose blend. Excipient selection therefore affects both active ingredients and the physical form of the co-crystal. Suppliers that can offer low-moisture, compendial-grade materials with strong regulatory documentation have the best positioning.

What is Seglentis and how does its dosage form affect excipient selection?

Seglentis is an immediate-release tablet approved by the FDA for the short-term management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate. It combines an NSAID, celecoxib, with the opioid analgesic tramadol hydrochloride.[1]

The product uses a celecoxib-tramadol co-crystal. This structure creates a formulation profile different from a simple physical mixture:

Formulation attribute	Commercial implication
Celecoxib has low aqueous solubility	Requires rapid-wetting and dissolution support
Tramadol hydrochloride is highly water soluble	Can dissolve rapidly and influence local tablet microenvironment
Co-crystal physical form must remain stable	Moisture, heat, milling, and compression require control
Immediate-release target	Disintegrant and wetting-agent performance are central
Controlled opioid substance	Manufacturing requires diversion controls and documented process security
Fixed-dose combination	Dose flexibility is narrower than for separate products

The excipient system must produce a tablet that disintegrates rapidly while avoiding excessive water exposure during granulation, storage, and dissolution testing.

What excipients are used in Seglentis?

The FDA-approved product uses a conventional immediate-release tablet platform. Public labeling identifies inactive ingredients including microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. The film coating contains standard coating components, including hypromellose, titanium dioxide, talc, and colorants.[1,2]

Excipient function	Likely Seglentis formulation role	Strategic priority
Microcrystalline cellulose	Diluent and compression aid	High
Croscarmellose sodium	Superdisintegrant	High
Povidone	Binder	Medium to high
Sodium lauryl sulfate	Wetting and dissolution aid	High
Colloidal silicon dioxide	Glidant and moisture-flow aid	Medium
Magnesium stearate	Lubricant	High because over-lubrication can slow dissolution
Hypromellose	Film former	Medium
Titanium dioxide and talc	Opacity and coating performance	Medium
Colorants	Product identification	Low from a performance perspective

The most commercially sensitive excipients are sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, and the cellulose-based diluent. These materials directly affect wetting, disintegration, blend flow, tablet hardness, and dissolution.

Which excipient strategy is most suitable for a celecoxib-tramadol co-crystal?

A direct-compression platform is the most commercially attractive starting point because it minimizes water exposure and reduces the risk of co-crystal conversion during processing. A dry-granulation process can be considered if the formulation requires higher density, better flow, or improved content uniformity.

Direct compression

Direct compression offers four advantages:

1. It reduces exposure to water and heat.
2. It shortens the manufacturing process.
3. It reduces solvent-management requirements.
4. It supports rapid scale-up through standard tablet equipment.

The main risk is poor flow or segregation caused by differences in particle size and density between the co-crystal and excipients. A co-processed cellulose-silica excipient or engineered-grade microcrystalline cellulose may improve flow without materially increasing the excipient burden.

Dry granulation

Roller compaction can improve flow and tablet weight uniformity. It is more appropriate when the active co-crystal has poor bulk density or when direct compression produces excessive weight variation.

The process must be optimized to avoid:

• Co-crystal fracture;
• Excessive fines;
• Changes in polymorphic or hydrate state;
• Slower dissolution from over-densification;
• Segregation during post-compaction blending.

Wet granulation

Wet granulation presents the highest formulation risk because moisture can influence the co-crystal and the dissolution behavior of celecoxib. It should be used only when direct compression and dry granulation cannot meet manufacturability targets. If aqueous granulation is required, low-water or nonaqueous processing, tight endpoint control, and solid-state characterization are important.

What excipients can improve Seglentis dissolution?

Sodium lauryl sulfate is the most obvious wetting-agent lever because celecoxib has low aqueous solubility. Its concentration must be controlled carefully. Excess surfactant can affect tablet strength, powder flow, gastrointestinal tolerability, and dissolution reproducibility.

Potential formulation approaches include:

Approach	Benefit	Risk
Sodium lauryl sulfate optimization	Improves wetting of celecoxib-rich particles	Excess can affect tolerability and dissolution profile
Crospovidone substitution or addition	Rapid capillary-driven disintegration	Can increase friability or alter compactability
Higher-performance croscarmellose grade	Supports rapid tablet breakup	May increase sensitivity to compression force
Copovidone or optimized povidone	Improves binding and content uniformity	Higher binder levels may slow disintegration
Co-processed excipient	Improves flow and compaction	May complicate regulatory comparability
Amorphous or porous silica	Enhances powder handling and surface wetting	Can increase moisture uptake
Mannitol or spray-dried lactose	Improves mouthfeel and tablet properties	May alter density and compatibility

The preferred commercial strategy is to retain the established excipient architecture unless a clearly superior dissolution or manufacturability profile is demonstrated. For a marketed product, an excipient change can create comparability, stability, and post-approval change-control work that exceeds the value of a modest manufacturing benefit.

What formulation patents protect Seglentis and related products?

Seglentis is protected primarily through intellectual property covering the celecoxib-tramadol co-crystal, pharmaceutical compositions, therapeutic use, and potentially manufacturing or solid-state characteristics. The relevant rights are distinct from patents covering routine tablet excipients.

IP category	Relevance to Seglentis	Generic-development impact
Co-crystal composition claims	Protect the active solid form	Highest barrier if claims remain enforceable
Pharmaceutical composition claims	Cover combinations with excipient systems or dosage forms	Can constrain formulation design-arounds
Method-of-use claims	Cover treatment of acute pain or related indications	May support litigation after ANDA filing
Solid-state and polymorph claims	Protect specific crystalline forms	Important for analytical characterization
Manufacturing claims	Cover preparation or isolation of the co-crystal	May affect API sourcing
Formulation claims	Cover immediate-release tablet compositions	Relevant if broad enough to capture generic tablets

FDA Orange Book listings, not the product label, determine the patents that an ANDA applicant must address. A definitive freedom-to-operate analysis requires review of the current Orange Book entries, patent-family prosecution history, terminal disclaimers, maintenance status, and claim scope.[3]

For Seglentis, the most important technical question is whether a generic applicant can use the same therapeutic combination while avoiding the claimed co-crystal form. If the listed claims require the co-crystal, a generic company may need to challenge validity, claim construction, or infringement rather than simply substitute a physical mixture.

When does Seglentis lose exclusivity?

Seglentis received FDA approval in October 2021 under NDA 214608. It is a small-molecule product, so its market-exclusivity framework is based on Hatch-Waxman, patent listings, and any applicable regulatory exclusivity. It is not a biologic and does not receive biosimilar exclusivity under the Biologics Price Competition and Innovation Act.[1,3]

Exclusivity element	Seglentis relevance
New chemical entity exclusivity	Generally not expected because celecoxib and tramadol were previously approved active ingredients
Fixed-combination exclusivity	May apply only if statutory requirements are met; it is not equivalent to NCE exclusivity
Orphan exclusivity	Not indicated for the approved acute-pain use
Patent protection	Potentially the principal barrier to ANDA launch
Pediatric exclusivity	Must be confirmed from FDA regulatory records
Paragraph IV risk	Depends on current Orange Book patent listings and ANDA timing

The practical loss-of-exclusivity date cannot be reduced to the 2021 approval date. Generic entry depends on the latest enforceable listed patent, any 30-month litigation stay, settlement terms, pediatric extension, and possible at-risk launch.

What paragraph IV challenges and litigation affect Seglentis?

A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The NDA holder or patent owner could respond with an infringement action within 45 days, potentially triggering a statutory 30-month stay of FDA approval under the Hatch-Waxman framework.[4]

The relevant litigation issues are likely to include:

• Whether the generic product contains the claimed celecoxib-tramadol co-crystal;
• Whether the ANDA formulation infringes composition or formulation claims;
• Whether manufacturing claims can be enforced against an independently sourced API;
• Whether method-of-use claims are relevant after section viii carve-outs;
• Whether settlement terms permit an agreed generic launch date;
• Whether a generic applicant can launch a non-infringing physical mixture.

No biosimilar litigation pathway applies because Seglentis is a small-molecule tablet. The principal competitive threat is an ANDA applicant, not a 351(k) biosimilar sponsor.

What generic entry risks exist for Seglentis?

Generic entry can occur through several routes:

Same co-crystal, alternative excipients

This is the closest generic pathway. The applicant would attempt to match the active solid form while using a different excipient system. The commercial risk depends on whether formulation patents claim broad excipient classes or narrow compositions.

Physical mixture of celecoxib and tramadol

A physical mixture could avoid a co-crystal claim but may face regulatory and therapeutic-equivalence issues. The product would need to demonstrate that its dosage form delivers the same active ingredients with equivalent performance. It could also fall outside the approved product’s formulation and intellectual-property position.

Separate generic products

Generic celecoxib and generic tramadol already exist as separate products. Prescribers and payers could use them as a substitute for Seglentis, although the regimen would not necessarily reproduce the same fixed-dose co-crystal product.

Authorized generic

An authorized generic or licensed alternative could reduce price pressure while preserving some control over channel access. This is a commercial option if patent settlements or market-share defense becomes necessary.

How strong is the Seglentis patent estate?

The estate’s strongest technical position is likely the co-crystal itself, provided the composition claims are enabled, supported, and not vulnerable to prior-art or obviousness challenges. Formulation patents are generally more valuable when they cover a narrow performance feature that generic applicants cannot easily reproduce, such as a defined dissolution profile, particle-size range, or solid-state form.

Patent-estate factor	Assessment
Co-crystal composition	Potentially strong if claim scope is broad and validity survives prior-art review
Routine excipient claims	Typically weaker and easier to design around
Method-of-use claims	Useful but may be limited by label carve-outs
Manufacturing claims	Strongest where process conditions are difficult to avoid
Solid-state claims	Important if the product requires a defined form
Commercial durability	Depends on patent expiry, settlement timing, and generic formulation options

The commercial value of the estate is therefore likely to be concentrated in active-form and solid-state claims rather than in standard tablet excipients.

What commercial opportunities exist for excipient suppliers?

The largest opportunities are not necessarily in replacing the listed excipients. They are in supplying higher-performance grades that improve manufacturing consistency while maintaining the same qualitative excipient profile.

High-value opportunities

Excipient suppliers can target:

• Low-moisture microcrystalline cellulose;
• Direct-compression cellulose with improved flow;
• High-functionality croscarmellose sodium;
• Low-peroxide povidone grades;
• Consistent pharmaceutical sodium lauryl sulfate;
• Magnesium stearate with controlled specific surface area;
• Co-processed diluent-disintegrant systems;
• Film-coating systems with reduced processing time;
• Excipient packages supported by extractables, elemental impurity, nitrosamine, and residual-solvent data.

The strongest value proposition is a documented reduction in blend variability, tablet defects, dissolution drift, or scale-up risk. Price competition alone is unlikely to create durable differentiation because most individual excipients are available from multiple qualified suppliers.

Contract manufacturing opportunities

Contract manufacturers can offer value through:

• Low-moisture direct compression;
• Contained handling of tramadol;
• Dedicated cleaning validation;
• Co-crystal solid-state monitoring;
• In-process dissolution or near-infrared testing;
• Flexible small-batch packaging;
• Controlled-substance security systems;
• Stability programs that compare excipient grades.

Seglentis is suitable for manufacturers that can handle both controlled-substance requirements and solid-state-sensitive APIs. That combination narrows the field of credible suppliers.

What is the FDA regulatory status of Seglentis?

Seglentis is FDA-approved as an immediate-release tablet for acute pain. The product contains an opioid and carries opioid-related warnings, including risks of addiction, abuse, misuse, respiratory depression, and interactions with other central nervous system depressants.[1]

The FDA regulatory considerations for an excipient change include:

• Dissolution comparison against the approved product;
• Assay and content uniformity;
• Stability under accelerated and long-term conditions;
• Solid-state characterization of the co-crystal;
• Tablet hardness, friability, and disintegration;
• Impurity and degradation-product profiling;
• Assessment of post-approval reporting category;
• Controlled-substance manufacturing controls.

An excipient change that alters dissolution or co-crystal stability may require more than routine annual-report documentation. The regulatory category depends on the specific change, the approved manufacturing process, and the supporting comparability package.

How does Seglentis compare with separate celecoxib and tramadol products?

Attribute	Seglentis	Separate celecoxib plus tramadol
Administration	One fixed-dose tablet	Two products or dosage forms
Dose flexibility	Limited	Greater
Co-crystal	Yes	No
Adherence	Potentially simpler	More complex
Generic substitution	Dependent on co-crystal and patent strategy	Broad existing generic availability
Payer economics	May face branded-product scrutiny	Often lower-cost generic alternatives
Formulation differentiation	High	Low
Clinical positioning	Fixed-dose acute-pain option	Flexible combination therapy

Seglentis has a product-design advantage, but its commercial durability depends on whether clinicians value the fixed-dose co-crystal enough to overcome lower-cost separate generic therapy.

What is the revenue exposure and competitive outlook?

Kowa Pharmaceuticals America is the U.S. commercial sponsor. Publicly available product materials do not establish a reliable standalone Seglentis revenue figure. Commercial exposure should therefore be modeled from prescription volume, net price, payer coverage, opioid restrictions, and substitution by generic celecoxib and tramadol.

The main competitive pressures are:

1. Low-cost separate generic components;
2. Opioid stewardship and prescribing restrictions;
3. Payer preference for generic alternatives;
4. Patent or formulation challenges;
5. Limited dose flexibility;
6. Potential generic entry after patent barriers expire or are settled.

The product’s strongest commercial segment is acute pain where a prescriber wants NSAID and opioid activity in a single tablet and where the patient is not adequately managed by nonopioid therapy alone.

Key Takeaways

• Seglentis is an immediate-release celecoxib-tramadol co-crystal tablet approved by the FDA in 2021.
• Its excipient strategy centers on rapid wetting, fast disintegration, tablet robustness, and protection of co-crystal integrity.
• Direct compression is the most commercially attractive manufacturing platform because it limits moisture and process complexity.
• Sodium lauryl sulfate, croscarmellose sodium, microcrystalline cellulose, povidone, and magnesium stearate are the most important performance excipients.
• The strongest patent value is likely in the co-crystal, solid-state, and manufacturing claims, not in routine tablet excipients.
• Seglentis faces ANDA risk rather than biosimilar risk.
• Separate generic celecoxib and tramadol products are the principal commercial substitutes.
• Excipient suppliers can compete through low-moisture grades, improved direct-compression performance, controlled variability, and regulatory documentation.
• A definitive generic-entry date requires current Orange Book patent data, patent prosecution review, and any Paragraph IV settlements.

Frequently Asked Questions

Can Seglentis be reformulated with different excipients?

Yes, but the change must preserve tablet performance, dissolution, stability, and co-crystal integrity. The regulatory reporting category depends on the specific excipient and manufacturing change.

Is Seglentis a biologic or biosimilar product?

No. Seglentis is a small-molecule oral tablet. Its generic competition would proceed through an ANDA rather than the biosimilar pathway.

Which excipient is most important for celecoxib dissolution in Seglentis?

Sodium lauryl sulfate is a key wetting-agent candidate because celecoxib has low aqueous solubility. Its level must be balanced against tablet performance and tolerability considerations.

Can a generic company avoid Seglentis patents by using separate celecoxib and tramadol tablets?

Separate tablets may avoid claims directed specifically to the co-crystal, but they would not necessarily be therapeutically or commercially equivalent to Seglentis. The strategy would depend on the scope of the listed patents and the regulatory pathway used.

What is the best commercial opportunity for a Seglentis excipient supplier?

The strongest opportunity is a qualified, low-moisture direct-compression excipient system that improves flow, content uniformity, tablet robustness, and dissolution reproducibility without requiring a major formulation redesign.

References

1. U.S. Food and Drug Administration. (2021). Seglentis (celecoxib and tramadol hydrochloride) tablets, prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Seglentis, celecoxib and tramadol hydrochloride tablet.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2017). Hatch-Waxman amendments and abbreviated new drug applications.